Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)
Tarcic, G., Walko, C.M., McLeod, H.L., Hicks, J.K., Barbash, Z., Edelheit, O., Miron, B., Vidne, M., Padron, E.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation
Wood, W.A, Walko, C.M, Rao, K.V, Whitley, J, Moore, D.T, Gabriel, D.A, Serody, J.S, Coghill, J.M, Shea, T.C
Published in Biology of blood and marrow transplantation (01.02.2009)
Published in Biology of blood and marrow transplantation (01.02.2009)
Get full text
Journal Article
Patients’ Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer
Brewer, N.T., DeFrank, J.T., Chiu, W.K., Ibrahim, J.G., Walko, C.M., Rubin, P., Olajide, O.A., Moore, S.G., Raab, R.E., Carrizosa, D.R., Corso, S.W., Schwartz, G., Peppercorn, J.M., McLeod, H.L., Carey, L.A., Irvin, W.J.
Published in Community genetics (01.01.2014)
Published in Community genetics (01.01.2014)
Get full text
Journal Article